BRIDGEWATER, N.J., Oct. 8, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that an abstract related to KRYSTEXXA® (pegloticase) has been selected for poster presentation at the American Society of Nephrology (ASN) Kidney Week 2013. The annual meeting will be held November 5-10, 2013, in Atlanta, GA.
Savient's abstract, #FR-PO417, entitled "Pegloticase, a Recombinant Uricase for the Treatment of Advanced Gout, Maintains Therapeutic Concentrations During Dialysis" will be presented in a poster session titled Dialysis: Epidemiology, Outcomes, and Clinical Trials; Non-Cardiovascular I, on Friday, November 8, 2013, from 10:00am to 12:00pm ET.
ABOUT SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. In the U.S., Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII and co-promotes Kineret® (anakinra) with Swedish Orphan Biovitrum AB (Sobi). For more information, please visit the Company's website at www.savient.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain information in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that are not statements of historical fact should be considered forward-looking statements. We often use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "may," "predict," "will," "would," "could," "should," "target" and similar expressions to identify forward-looking statements. Actual results or events could differ materially from those indicated in forward-looking statements as a result of risks and uncertainties. For a discussion of some of the risks and important factors that we believe could cause actual results or events to differ from the forward-looking statements that we make, see the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results or events to differ from those contained in any forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking statements contained in this press release. Any forward-looking statements speak only as of the date of this press release. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
Savient Pharmaceuticals, Inc. John P. Hamill Co-President and Chief Financial Officer email@example.com (732) 418-9300
Burns McClellan Caitlyn E. Murphy firstname.lastname@example.org (212) 213-0006
SOURCE Savient Pharmaceuticals, Inc.